 |
Cyclacel Reports Third Quarter 2012 Financial Results
Nov 12, 2012
|
27.8 KB |
|
| |
- Enrollment in SEAMLESS Phase 3 study of sapacitabine proceeding as planned; updated survival data from the pilot/lead-in stage of SEAMLESS to be presented at the upcoming annual meeting of the American Society of Hematology -- Conference Call Scheduled November 12, 2012 at 4:30 p.m. Eastern Time -
BERKELEY HEIGHTS, N.J., Nov. 12, 2012 (GLOBE ...
|
|
Cyclacel Pharmaceuticals to Announce Release of Third Quarter 2012 Financial Results
Nov 9, 2012
|
12.4 KB |
|
| |
BERKELEY HEIGHTS, N.J., Nov. 9, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders will announce third quarter 2012 financial ...
|
|
Cyclacel to Present at Lazard Healthcare Conference
Nov 7, 2012
|
12.2 KB |
|
| |
BERKELEY HEIGHTS, N.J., Nov. 7, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced today that Spiro Rombotis, Presi...
|
|
Personalized Medicine Potential of Cyclacel's Innovative and Diverse Oncology Pipeline Highlighted at NCRI Cancer Conference
Nov 6, 2012
|
17.7 KB |
|
| |
BERKELEY HEIGHTS, N.J., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), announced today multiple posters presented on the Company's sapacitabine and on its Polo-Like Kinase 1 (Plk1) inhibitors during the 8th National Cancer Research Institute (NCRI) Cancer Conference being held...
|
|
Cyclacel Receives $1.9 Million Translational Medicine Grant Award From the UK Biomedical Catalyst to Advance Its CYC065 Targeted Drug for Leukemias
Nov 5, 2012
|
18.4 KB |
|
| |
BERKELEY HEIGHTS, N.J. and DUNDEE, United Kingdom, Nov. 5, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP); ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced t...
|
|
Cyclacel Announces Publication of Phase 2 Results for Sapacitabine in Elderly AML Patients in the Lancet Oncology
Nov 1, 2012
|
20.2 KB |
|
| |
Study Provides Support for SEAMLESS, an Ongoing, Phase 3, Registration-Directed Trial in Elderly Patients With Newly Diagnosed AMLUpdated Survival Data From a Pilot Study and Lead-In Phase of SEAMLESS to be Presented at the 2012 Annual Meeting of the American Society of Hematology
BERKELEY HEIGHTS, N.J., Nov. 1, 2012 (GLOBE NEWSWIRE) -- Cyclace...
|
|
Cyclacel's Sapacitabine Nearly Doubles Expected Survival of Elderly Patients With MDS After Front-Line Therapy Failure
Oct 15, 2012
|
19.6 KB |
|
| |
BERKELEY HEIGHTS, N.J., Oct. 15, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), will host a conference call today to discuss updated data from an ongoing, multicenter, Phase 2 randomized trial of oral sapacitabine capsules, the Company's lead product candidate, in older patients with ...
|
|
Updated Phase 2 Survival Data of Cyclacel's Sapacitabine for MDS Presented at The Eighth Annual Hematologic Malignancies 2012 Conference
Oct 12, 2012
|
21.6 KB |
|
| |
BERKELEY HEIGHTS, N.J., Oct. 12, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) announced that updated data from an ongoing, multicenter, Phase 2 randomized trial of oral sapacitabine capsules, the Company's lead product candidate, in older patients with intermediate-2 or high-risk mye...
|
|
Cyclacel to Present at BIO Investor Forum
Oct 2, 2012
|
12.3 KB |
|
| |
BERKELEY HEIGHTS, N.J., Oct. 2, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced today that Spiro Rombotis, Presi...
|
|
Cyclacel Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement
Sep 13, 2012
|
12.1 KB |
|
| |
BERKELEY HEIGHTS, N.J., Sept. 13, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced today that it has received not...
|
|
Cyclacel to Present at Stifel Nicolaus 2012 Healthcare Conference
Aug 29, 2012
|
12.3 KB |
|
| |
BERKELEY HEIGHTS, N.J., Aug. 29, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced today that Spiro Rombotis, Pres...
|
|
Cyclacel Announces Reverse Stock Split
Aug 24, 2012
|
14.4 KB |
|
| |
BERKELEY HEIGHTS, N.J., Aug. 24, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced a 1-for-7 reverse stock s...
|
|
Cyclacel Reports Second Quarter 2012 Financial Results
Aug 14, 2012
|
28.1 KB |
|
| |
BERKELEY HEIGHTS, N.J., Aug. 14, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC), (Nasdaq:CYCCP); Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders today reported its financial results and ...
|
|
Cyclacel Pharmaceuticals to Announce Release of Second Quarter 2012 Financial Results
Aug 10, 2012
|
13.3 KB |
|
| |
BERKELEY HEIGHTS, N.J., Aug. 10, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders will announce second quarter 2012 financia...
|
|
Cyclacel Presents Phase 1 Data of Sequential Sapacitabine and Seliciclib in Advanced Solid Tumors at ASCO Annual Meeting
Jun 4, 2012
|
20.5 KB |
|
| |
BERKELEY HEIGHTS, N.J., June 4, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced new data from an open label, single arm, Phase 1 escalation trial of the Company's two product candidates, sapacitabine, a nucleoside analogue, and seliciclib, a CDK inhibitor, as an orally-...
|
|
Cyclacel Presents New Phase 2 Data of Sapacitabine for MDS at ASCO Annual Meeting
Jun 1, 2012
|
19.2 KB |
|
| |
BERKELEY HEIGHTS, N.J., June 1, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced new data from an ongoing, multicenter, Phase 2 randomized trial of oral sapacitabine capsules, the Company's lead product candidate, in older patients with myelodysplastic syndromes (MDS) af...
|
|
Cyclacel to Report New Sapacitabine Clinical Data at the American Society of Clinical Oncology Annual Meeting
May 17, 2012
|
14.9 KB |
|
| |
BERKELEY HEIGHTS, N.J., May 17, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), announced today that new clinical data for oral sapacitabine capsules, the Company's lead product candidate, will be presented as posters during the 2012 American Society of Clinical Oncology (ASCO) Annual ...
|
|
Cyclacel Reports First Quarter 2012 Financial Results
May 14, 2012
|
24.2 KB |
|
| |
BERKELEY HEIGHTS, N.J., May 14, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP); (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and ...
|
|
Cyclacel Announces Completion of Enrollment in Investigator-Initiated, Phase 2/3 Randomized Trial Comparing Sapacitabine to Low Dose Cytarabine
May 14, 2012
|
18.3 KB |
|
| |
BERKELEY HEIGHTS, N.J., May 14, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced today completion of enrollment of the Phase 2 portion of the investigator-initiated, Phase 2/3 multicenter, randomized trial comparing sapacitabine to low dose cytarabine (the "Pick a Winner Pr...
|
|
Cyclacel Pharmaceuticals to Announce Release of First Quarter 2012 Financial Results
May 8, 2012
|
13.2 KB |
|
| |
BERKELEY HEIGHTS, N.J., May 8, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP); (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders will announce first quarter 2012 financial ...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter